SCHEMBL7149853

SCHEMBL7149853

O=C(O)CCCN1C(=O)C(=Cc2ccc(OCc3ccccc3)cc2OCc2ccccc2)SC1=S

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 5/20 0.81
PSMD14 O00487 1/20 0.68
PLEC Q15149 1/20 0.68
KMT2A Q03164 5/20 0.66
MEN1 O00255 4/20 0.66
PPARG P37231 1/20 0.64
ADAMTS5 Q9UNA0 2/20 0.63
APAF1 O14727 1/20 0.63
AKR1B1 P15121 8/20 0.58
PTPN1 P18031 6/20 0.58
MMP3 P08254 2/20 0.58
MMP13 P45452 2/20 0.58
GFER P55789 1/20 0.58
PTPN2 P17706 2/20 0.55
KDM4E B2RXH2 1/20 0.55
FFAR1 O14842 1/20 0.55
ALDH1A1 P00352 1/20 0.55
MAPT P10636 1/20 0.55
APEX1 P27695 1/20 0.55
RECQL P46063 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7401104 0.94 KMT2A (0.73) POLBPSMD14PLECKMT2AMEN1
SCHEMBL7150753 0.94 POLB (0.82) POLBPSMD14PLECKMT2AMEN1
SCHEMBL12008456 0.90 POLB (1.00) POLBPSMD14PLECKMT2AMEN1
SCHEMBL7147356 0.89 PTPN1 (0.73) POLBKMT2AMEN1ADAMTS5AKR1B1
SCHEMBL7172539 0.88 KMT2A (0.75) POLBPSMD14PLECKMT2AMEN1
SCHEMBL7172537 0.88 KMT2A (0.75) POLBPSMD14PLECKMT2AMEN1
SCHEMBL6887184 0.86 KMT2A (0.75) POLBPSMD14PLECKMT2AMEN1
SCHEMBL6887183 0.86 KMT2A (0.75) POLBPSMD14PLECKMT2AMEN1
SCHEMBL12008459 0.86 AKR1B1 (0.78) POLBPSMD14PLECKMT2AMEN1
SCHEMBL12008454 0.85 KMT2A (0.89) POLBPSMD14PLECKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6506755-B2 5-((2,4-bis-(4-methylphenylmethoxy)phenyl)methylene)-4-oxo-2-thioxo-3 -thiazolidineacetic acid, for example; treatment and prophylaxis of tumors and tumor metastasis HOFFMANN-LA ROCHE INC. 2003-01-14 US disclosed
US-20020037901-A1 Thiazolidinecarboxyl acids HOFFMANN-LA ROCHE INC. 2002-03-28 US disclosed
EP-1189894-A1 THIAZOLIDINE CARBOXYLIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER F. HOFFMANN-LA ROCHE AG (CH) 2002-03-27 EP disclosed
WO-2001057006-A1 THIAZOLIDINE CARBOXYLIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER F. HOFFMANN-LA ROCHE AG (CH) 2001-08-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020037901-A1 Thiazolidinecarboxyl acids TPMT, NAT1, THRA POLB 3974/4885PSMD14 4553/4885PLEC 3676/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.